Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Consensus Target Price of $6.00 According to Analysts

Spero Therapeutics, Inc. (NASDAQ:SPRO) has been given an average recommendation of “Hold” by the five analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $6.00.

A number of research firms recently weighed in on SPRO. Compass Point raised shares of Spero Therapeutics to a “neutral” rating in a report on Monday, September 14th. Zacks Research raised shares of Spero Therapeutics to a “hold” rating in a research report on Monday, September 14th. HC Wainwright raised their target price on shares of Spero Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Monday, September 14th. Weiss Ratings cut shares of Spero Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday. Finally, Cantor Fitzgerald began coverage on shares of Spero Therapeutics in a research note on Wednesday. They issued an “overweight” rating and a $6.00 price target for the company.

Institutional Investors Weigh In On Spero Therapeutics

Large investors have recently made changes to their positions in the company. Susquehanna Fundamental Investments LLC purchased a new position in Spero Therapeutics during the second quarter worth $36,000. Global Retirement Partners LLC bought a new position in shares of Spero Therapeutics during the 2nd quarter worth $55,000. GSA Capital Partners LLP purchased a new position in shares of Spero Therapeutics during the second quarter valued at $632,000. BlackRock Inc. purchased a new position in shares of Spero Therapeutics during the second quarter valued at $1,314,000. Finally, Alphabet Inc. bought a new stake in shares of Spero Therapeutics in the second quarter valued at about $1,967,000. 25.60% of the stock is owned by institutional investors.

Spero Therapeutics Stock Up 6.5%

Spero Therapeutics stock opened at $1.14 on Wednesday. Spero Therapeutics has a 1-year low of $1.04 and a 1-year high of $3.08. The firm’s fifty day moving average price is $1.18 and its two-hundred day moving average price is $2.00.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.01. Analysts anticipate that Spero Therapeutics will post -0.58 earnings per share for the current fiscal year.

About Spero Therapeutics

Spero Therapeutics, Inc (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company’s research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens.

Spero’s lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.